Tags

Type your tag names separated by a space and hit enter

Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.
Expert Opin Drug Saf. 2015 Aug; 14(8):1237-47.EO

Abstract

INTRODUCTION

Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease. To estimate the association between ICS and pneumonia among users of ICS relative to non-ICS users and to examine whether this risk is dose related, class related and what's its association with the pneumonia-mortality or overall mortality.

AREAS COVERED

Through a comprehensive literature search of MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov from inception to February 2015, we identified randomized controlled trials of ICS therapy lasting at least 6 months. We conducted meta-analyses to generate summary estimates comparing ICS with non-ICS treatment on the risk of pneumonia.

EXPERT OPINION

ICS alone or in combination with long-acting β-agonists are associated with an increased risk of pneumonia but have no effect on pneumonia related mortality. It is important to identify those patients to benefit the most from ICS, as those with frequent exacerbations, a severe airway obstruction, a positive bronchodilator test or a sputum eosinophilia despite treatment.

Authors+Show Affiliations

Sotiria Hospital, 6th Respiratory Department , Mesogion 152, 11527, Athens , Greece +30 21 0776 3458 ; mliapikou@yahoo.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review

Language

eng

PubMed ID

26113207

Citation

Liapikou, Adamantia, et al. "Managing the Safety of Inhaled Corticosteroids in COPD and the Risk of Pneumonia." Expert Opinion On Drug Safety, vol. 14, no. 8, 2015, pp. 1237-47.
Liapikou A, Toumbis M, Torres A. Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opin Drug Saf. 2015;14(8):1237-47.
Liapikou, A., Toumbis, M., & Torres, A. (2015). Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opinion On Drug Safety, 14(8), 1237-47. https://doi.org/10.1517/14740338.2015.1057494
Liapikou A, Toumbis M, Torres A. Managing the Safety of Inhaled Corticosteroids in COPD and the Risk of Pneumonia. Expert Opin Drug Saf. 2015;14(8):1237-47. PubMed PMID: 26113207.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. AU - Liapikou,Adamantia, AU - Toumbis,Michael, AU - Torres,Antoni, Y1 - 2015/06/25/ PY - 2015/6/27/entrez PY - 2015/6/27/pubmed PY - 2016/3/22/medline KW - chronic obstructive pulmonary disease KW - inhaled corticosteroids KW - long-acting β-agonists KW - mortality KW - pneumonia SP - 1237 EP - 47 JF - Expert opinion on drug safety JO - Expert Opin Drug Saf VL - 14 IS - 8 N2 - INTRODUCTION: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease. To estimate the association between ICS and pneumonia among users of ICS relative to non-ICS users and to examine whether this risk is dose related, class related and what's its association with the pneumonia-mortality or overall mortality. AREAS COVERED: Through a comprehensive literature search of MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov from inception to February 2015, we identified randomized controlled trials of ICS therapy lasting at least 6 months. We conducted meta-analyses to generate summary estimates comparing ICS with non-ICS treatment on the risk of pneumonia. EXPERT OPINION: ICS alone or in combination with long-acting β-agonists are associated with an increased risk of pneumonia but have no effect on pneumonia related mortality. It is important to identify those patients to benefit the most from ICS, as those with frequent exacerbations, a severe airway obstruction, a positive bronchodilator test or a sputum eosinophilia despite treatment. SN - 1744-764X UR - https://www.unboundmedicine.com/medline/citation/26113207/Managing_the_safety_of_inhaled_corticosteroids_in_COPD_and_the_risk_of_pneumonia_ L2 - https://www.tandfonline.com/doi/full/10.1517/14740338.2015.1057494 DB - PRIME DP - Unbound Medicine ER -